FDA/CDC Active Surveillance System Could Assess Effect Of Safety Measures
A collaborative national electronic active surveillance system co-sponsored by FDA and the Centers for Disease Control & Prevention could be used to examine the impact of safety measures on the number of adverse drug events, CDC medical officer Dan Budnitz said July 7
You may also be interested in...
FDA should develop an active surveillance system using prescription drug claims data from the Medicare population to supplement its existing drug safety system, members of the agency's Drug Safety & Risk Management Advisory Committee said May 18 and 19
FDA has expanded its adverse drug event active surveillance program into 65 emergency rooms nationwide
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011